Details for New Drug Application (NDA): 050716
✉ Email this page to a colleague
The generic ingredient in NEORAL is cyclosporine. There are eighteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.
Summary for 050716
Tradename: | NEORAL |
Applicant: | Novartis |
Ingredient: | cyclosporine |
Patents: | 0 |
Pharmacology for NDA: 050716
Mechanism of Action | Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors |
Medical Subject Heading (MeSH) Categories for 050716
Suppliers and Packaging for NDA: 050716
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
NEORAL | cyclosporine | SOLUTION;ORAL | 050716 | NDA | Novartis Pharmaceuticals Corporation | 0078-0274 | 0078-0274-22 | 1 BOTTLE in 1 CARTON (0078-0274-22) / 50 mL in 1 BOTTLE |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 100MG/ML | ||||
Approval Date: | Jul 14, 1995 | TE: | AB1 | RLD: | Yes |
Expired US Patents for NDA 050716
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | NEORAL | cyclosporine | SOLUTION;ORAL | 050716-001 | Jul 14, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | NEORAL | cyclosporine | SOLUTION;ORAL | 050716-001 | Jul 14, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | NEORAL | cyclosporine | SOLUTION;ORAL | 050716-001 | Jul 14, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | NEORAL | cyclosporine | SOLUTION;ORAL | 050716-001 | Jul 14, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | NEORAL | cyclosporine | SOLUTION;ORAL | 050716-001 | Jul 14, 1995 | ⤷ Sign Up | ⤷ Sign Up |
Novartis | NEORAL | cyclosporine | SOLUTION;ORAL | 050716-001 | Jul 14, 1995 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription